abstract |
The present disclosure relates to antisense oligonucleotides, which target ANGPTL2 mRNA in a cell, leading to reduced expression of ANGPTL2 protein. Reduction of NGPTL2 protein expression is beneficial for the treatment of certain medical disorders, such as those associated with abnormal ANGPTL2 expression and/or activity, e.g., cardiovascular-related diseases or disorders. |